Expression of Smad4 and Smad7 of BMP signaling pathway in oral squamous cell carcinoma

Abstract

Abstract: PURPOSE: To observe the changes of the expressions of Smad4 and Smad7 in oral squamous cell carcinoma and adjacent normal tissue, and to investigate the effects of Smad4 and Smad7 on occurrence and development of oral squamous cell carcinoma (OSCC). METHODS: Seventy-two cases with OSCC which were pathologically confirmed were included in the study. Cancer tissue and adjacent normal tissue were taken to make slices. SP immunohistochemical method was used to detect the expression of Smad4 and Smad7 in oral squamous cell carcinoma and adjacent normal tissue. SPSS11.5 software package was used for statistical analysis. RESULTS: The positive expression rate of Smad4 protein was 69.44% in adjacent normal tissues, and it was 45.83% in oral squamous cell carcinoma(P<0.05). The positive expression rate of Smad4 was lower when the degree of differentiation decreased; The positive expression rate of Smad4 with lymph node metastasis was 22.50%, while it was 65.63% without lymph node metastasis(P<0.05). The positive expression rate of Smad7 protein in adjacent normal tissues was 19.44%, and it was 83.33% (P<0.05) in oral squamous cell carcinoma, the positive expression rate of Smad7 was higher when the degree of differentiation decreased. The positive expression rate of Smad7 with lymph node metastasis was 92.50%, while it was 68.75%(P<0.05) without lymph node metastasis. CONCLUSIONS: The expression of Smad4 is significantly reduced in cancer tissues and the expression is lower when the degree of differentiation decreased; the expression rate of Smad4 with lymph node metastasis is lower compared with those without lymph node metastasis. Smad7 has the opposite effect. Loss of expression of Smad4 may contribute to the development and metastasis of oral squamous cell carcinoma；Over-expression of Smad7 may promote the development and metastasis of oral squamous cell carcinoma. The inhibition of BMP/Smads signaling pathway may result in the occurrence and development of oral squamous cell carcinoma continually.

Key words: BMP, Oral squamous cell carcinoma, Smad4, Smad7, Signaling pathway

CLC Number:

R739.8

LIU Duan-qin, ZHANG Jun, SONG Hong-ning, ZHENG Jun, WANG Xu-xia,. Expression of Smad4 and Smad7 of BMP signaling pathway in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2013, 22(5): 492-497.

References

[1] Urist MR, DeLange RJ, Finerman GA. Bone cell differentiation and growth factors[J]. Science, 1983, 220(4598): 680-686.
[2] Wen XZ, Miyake S, Akiyama Y, et al. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells [J]. Biochem Biophys Res Commun, 2004, 316(1): 100-106.
[3] Heikinheimo KA, Laine MA, Ritvos OV, et al. Bone morphogenetic protein 6 is a marker of serous acinar cell differentiation in normal and neoplastic human salivary gland[J]. Cancer Res, 1999, 59(22): 5815-5821.
[4] 傅升, 金岩, 何黎升, 等. 骨形成蛋白(BMP)-2/4与IA型BMP受体在口腔鳞癌中的表达[J]. 实用口腔医学杂志, 2001, 17(6): 476-478.
[5] Sekelsky JJ, Newfeld SJ, Raftery LA, et al. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic functionin Drosophila melanogaster[J]. Genetics, 1995, 139(3): 1347-1358.
[6] Arai T, Akiyama Y, Okabe S, et al. Genomic structure of the human Smad3 gene and its infrequent alteration in colorectal cancers[J]. Cancer Lett, 1998, 122(1-2): 157-163.
[7] Zhang Y, Feng X, We R, et al. Receptor-associated Mad homologues synergize as effectors of the TGF-β responses[J]. Nature, 1996, 383(6596): 168-172.
[8] Wu G, Chen YG, Ozdamar B, et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation[J]. Science, 2000, 287(5450): 92-97.
[9] Sirard C, Kim S, Mirtsos C, et al. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling[J]. J Biol Chem,2000,275(3): 2063-2070.
[10] Lin X, Liang M, Liang YY, et al. Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4[J]. J Biol chem, 2003, 278(21): 18714-18719.
[11] Muro-Cacho CA, Rosario-Ortiz K, Livingston S, et al. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2[J]. Clin Cancer Res, 2001, 7(6): 1618-1626.
[12] Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types[J]. Cancer Res, 1996, 56(11): 2527-2530.
[13] Tanaka T, Watanabe T, Kazama Y, et al. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer a study matched for tumor depth and pathology[J]. J Surg Oncol, 2008, 97(1): 69-73.
[14] Kim SK, Fan Y, Papadimitrakopoulou V, et al. DPC4, a candidate tumor suppression gene, is altered infrequently in head and neck squamous cell carcinoma[J]. Cancer Res, 1996, 56(11): 2519-2521.
[15] Deng H, Ravikumar TS, Yang WL. Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells[J]. Cancer Lett,2009,281(2): 220-231.
[16] 蔡传宝,陶学金,朱声荣,等. TGF-β1、Smad4和CyclinD1在口腔鳞癌中的表达和意义[J].口腔医学研究,2007,23(1):14-16.
[17] Inamoto S, Iwata S, Inamoto T, et al. Crk-associated substrate lymphocyte type regulates transforming growth factor-β signaling by inhibiting Smad6 and Smad7[J]. Oncogene, 2007, 26(6): 893-904.
[18] Kim YH, Lee HS, Lee HJ, et al. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas[J]. Ann Oncol, 2004, 15(4): 574-580.
[19] Kleeff J, shiwata T, Maruyama H, et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer[J]. Oncogene, 1999, 18(39): 5363-5372.